<2,3-Dichlor-4-(5-carboxamido-3-ethyl-6-methyl-pyridin-2-yl)phenoxy>essigsaeure | 142891-49-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: <2,3-Dichlor-4-(5-carboxamido-3-ethyl-6-methyl-pyridin-2-yl)phenoxy>essigsaeure
• 英文别名: 2-[4-(5-Carbamoyl-3-ethyl-6-methylpyridin-2-yl)-2,3-dichlorophenoxy]acetic acid
• CAS: 142891-49-4
• 化学式: C₁₇H₁₆Cl₂N₂O₄
• 分子量: 383.231
• InChiKey: AWBBQNBMHAQGKM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.4
• 重原子数：
  25
• 可旋转键数：
  6
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.24
• 拓扑面积：
  103
• 氢给体数：
  2
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  <2,3-Dichlor-4-(3-ethyl-5-methoxycarbonyl-6-methyl-pyridin-2-yl)phenoxy>-essigsaeure 在 ammonium hydroxide 作用下， 反应 48.0h， 以65%的产率得到<2,3-Dichlor-4-(5-carboxamido-3-ethyl-6-methyl-pyridin-2-yl)phenoxy>essigsaeure
  参考文献：
  名称：

  来自依他宁酸的吡啶化合物，第 2 部分

  摘要：

  烟酰胺 4、5-羟甲基化合物 5 和 5,6-双（羟甲基）吡啶 10 分五个步骤由烟酸甲酯 2 生产。N-氧化物 3 与硝酸反应生成硝基芳族化合物 11。

  DOI：

  10.1002/ardp.19923250610

文献信息

• Aryl substituted pyridines and the use thereof
  申请人：Shao Bin

  公开号：US20070010554A1

  公开（公告）日：2007-01-11

  This invention relates aryl substituted pyridines of Formula I: or a pharmaceutically acceptable salt, prodrug or solvate thereof, wherein Ar and R 1 —R 4 are set in the specification. The invention is also directed to the use of compounds of Formula I for the treatment of neuronal damage following global and focal ischemia, for the treatment or prevention of neurodegenerative conditions such as amyotrophic lateral sclerosis (ALS), and for the treatment, prevention or amelioration of both acute or chronic pain, as antitinnitus agents, as anticonvulsants, and as antimanic depressants, as local anesthetics, as antiarrhythmics and for the treatment or prevention of diabetic neuropathy.
• Aryl Substituted Pyridines and the Use Thereof
  申请人：SHAO Bin

  公开号：US20100048626A1

  公开（公告）日：2010-02-25

  This invention relates aryl substituted pyridines of Formula I: or a pharmaceutically acceptable salt, prodrug or solvate thereof, wherein Ar and R 1 -R 4 are set in the specification. The invention is also directed to the use of compounds of Formula I for the treatment of neuronal damage following global and focal ischemia, for the treatment or prevention of neurodegenerative conditions such as amyotrophic lateral sclerosis (ALS), and for the treatment, prevention or amelioration of both acute or chronic pain, as antitinnitus agents, as anticonvulsants, and as antimanic depressants, as local anesthetics, as antiarrhythmics and for the treatment or prevention of diabetic neuropathy.
• US7579367B2
  申请人：——

  公开号：US7579367B2

  公开（公告）日：2009-08-25
• US7943643B2
  申请人：——

  公开号：US7943643B2

  公开（公告）日：2011-05-17
• Pyridin-Verbindungen aus Etacrynsäure, 2. Mitteilung
  作者：Klaus Görlitzer、Wolfgang Düwel

  DOI：10.1002/ardp.19923250610

  日期：——

  Ausgehend vom Nicotinsäuremethylester 2 werden das Nicotinamid 4, die 5‐Hydroxymethyl‐Verbindung 5 und über fünf Stufen das 5,6‐Bis(hydroxy‐methyl)pyridin 10 hergestellt. Das N‐Oxid 3 reagiert mit Salpetersäure zum Nitroaromaten 11.

  烟酰胺 4、5-羟甲基化合物 5 和 5,6-双（羟甲基）吡啶 10 分五个步骤由烟酸甲酯 2 生产。N-氧化物 3 与硝酸反应生成硝基芳族化合物 11。